ROSG Key Stats
Street Insider07/22 09:35
Street Insider07/10 11:28
Street Insider07/10 09:02
Street Insider06/26 09:51
|04/01/2014 10:00 EDT||Misc||Rosetta Genomics, Ltd. Q4 2013 Earning Conference Call|
|03/31/2014||Earnings||Rosetta Genomics, Ltd. Q4 2013 Earning Result.|
|09/10/2013 10:00 EDT||Misc||Rosetta Genomics to Host Business Update Conference Call on September 10, 2013|
|09/09/2013||Earnings||Rosetta Genomics Announces Q2 2013 Results.|
|08/05/2013||Misc||AGM Event for Rosetta Genomics Ltd.|
ROSG Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Rosetta Genomics is up 12.29% over the last year vs S&P 500 Total Return up 19.65%, BG Medicine down 19.70%, and LipoScience down 47.49%.
Income Statement View Statement
Balance Sheet View Statement
Y-Ratings for ROSG
Portfolio Strategies Featuring ROSG
Did Rosetta Genomics make it into our Portfolio Strategies?
Start your YCharts membership now to find out.
- Sector: Healthcare
- Industry: Diagnostics & Research
- Company Website: http://www.rosettagenomics.com
- IR Website: http://www.rosettagenomics.com/investors
- HQ Country: Israel
- HQ State/Province: N/A
- Incorporation Country: Israel
- Incorporation State/Province: N/A
- Est. Current Fiscal Quarter End: June 30, 2014
- Est. Current Fiscal Year End: December 31, 2014
- Last Fiscal Quarter End: December 31, 2013
- Last Fiscal Year End: December 31, 2013
Rosetta Genomics Ltd is engaged in the development and commercialization of new diagnostic tests and therapeutics based on a group of genes known as microRNAs.
ROSG Excel Add-In Codes
- Name: =YCI("ROSG","name")
- Description: =YCI("ROSG","description")
- Sector: =YCI("ROSG","sector")
- Industry: =YCI("ROSG","industry")
- Est. Current Fiscal Year End: =YCI("ROSG","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.